ArticleOncogene2004
An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 62 citations in OpenAlex.
- Matrix Metalloproteinases as Candidate Antigenic Determinants for Anti-Tumor Autoantibodies in Human Ovarian Cancer: A Post Hoc Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Conformational ligand-directed targeting of calcium-dependent receptors in acute trauma.Med (New York, N.Y.) · 2025Article
- Article
- An antivascular vaccine to boost self-immunity and strike the tumor.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer.Cancer biomarkers : section A of Disease markers · 2017Review
- Ligand-targeted theranostic nanomedicines against cancer.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Identification of disease-specific motifs in the antibody specificity repertoire via next-generation sequencing.Scientific reports · 2016Article
- The role of autoimmunity in premature ovarian failure.Iranian journal of reproductive medicine · 2015Review
- Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- The double-edged sword: conserved functions of extracellular hsp90 in wound healing and cancer.Cancers · 2014Article
- Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer.Journal of ovarian research · 2014Article
- Combinatorial approaches for the identification of brain drug delivery targets.Current pharmaceutical design · 2014Review
- Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells.Molecular biology reports · 2013Article
- Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.The Journal of biological chemistry · 2012Article
- Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.Neoplasia (New York, N.Y.) · 2012Article
- Anti-HSP90 autoantibodies in sera of infertile women identify a dominant, conserved epitope EP6 (380-389) of HSP90 beta protein.Reproductive biology and endocrinology : RB&E · 2011Article
- Exploring the immunoproteome for ovarian cancer biomarker discovery.International journal of molecular sciences · 2011Review
- Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure.Fertility and sterility · 2010Article
- Phage display in molecular imaging and diagnosis of cancer.Chemical reviews · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
To gain insight into the mechanisms of molecular recognition and humoral immune response in ovarian cancer, we used fingerprinting, a phage display-based combinatorial selection to isolate peptide ligands to tumor-related antibodies present in ascites from patients with advanced disease. First, we have isolated a consensus motif (sequence CVPELGHEC) in 86% of the peptides screened; this enriched motif was selected from a total of 10(8)-10(9) unique random sequences present in the library. Next, we identified the heat-shock protein 90 kDa (HSP90) as the native antigen mimicked by the motif. Finally, we evaluated the expression of HSP90 and the presence of antibodies against the HSP90-mimic peptide in a large panel of ovarian cancer patients and controls. In tissue microarrays, we show that the expression of HSP90 is ubiquitous. However, the corresponding humoral immune response against HSP90 is restricted to a subset of patients with stage IV disease. Together, these results show that screening humoral response can identify tumor antigens that may serve as molecular targets in ovarian cancer. Recognition of such relevant proteins in the immunobiology of malignant tumors may lead to the development of therapies
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.